Storia in 11 fonti

AbbVie to buy Apogee Therapeutics in nearly $11B deal

AbbVie is buying Apogee Therapeutics, the developer of an experimental atopic dermatitis drug, for nearly $11B, continuing a run of pharma acquisitions.

Raccontata da

markets.businessinsider.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo1 mese fa

AbbVie to buy Apogee Therapeutics in nearly $11B deal

AbbVie acquires Apogee for $10.9B to add zumilokibart, an immunology drug dosed 2–4 times yearly for inflammatory diseases. The deal signals pharma's trend toward consolidation via focused biotech acquisitions—key signal for partnership and M&A strategy.

originale

Timeline cronologica

venerdì 19 giugno 2026·markets.businessinsider.com
M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics
Shares in biotechnology company Apogee Therapeutics (APGE) are set to start the new week off in great shape on reports that it could be swallowe...
venerdì 19 giugno 2026·wiwo.de
Pharmaindustrie: AbbVie wohl vor Übernahme von Biotechfirma Apogee Therapeutics
Der Pharmariese aus den USA plant offenbar den Kauf von Apogee Therapeutics. Das Angebot stellt einen deutlichen Aufschlag dar.

AbbVie to buy Apogee Therapeutics in nearly $11B deal

Confronto fonti

AbbVie to buy Apogee Therapeutics in nearly $11B deal

Timeline cronologica

M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics

Pharmaindustrie: AbbVie wohl vor Übernahme von Biotechfirma Apogee Therapeutics

AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics

AbbVie Goes On The Offensive With $10.9 Billion Takeover

AbbVie compra Apogee per 10,9 mld $ | MilanoFinanza News

AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates

AbbVie ultima la compra de la 'biotech' Apogee por 9.500 millones

FT: AbbVie está perto de comprar Apogee Therapeutics por US$ 11 bi

AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates

AbbVie to buy Apogee Therapeutics in nearly $11B deal

Pharma: AbbVie schluckt Biotechfirma Apogee für 10,9 Milliarden Dollar

AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition - AbbVie (NYSE:ABBV), Apogee Ther

AbbVie Goes On The Offensive With $10.9 Billion Takeover

AbbVie compra la 'biotech' Apogee por 10.900 millones de d�lares

Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monda

AbbVie compra Apogee per 10,9 mld $ | MilanoFinanza News

AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - AbbVie (NYSE:ABBV), Apogee Therapeutic

AbbVie's Big Immunology Acquisition